Skip to content

ADMA Biologics ADMA Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Zymeworks logo
ZymeworksZYME
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Quest Diagnostics logo
Quest DiagnosticsDGX
Abbott logo
AbbottABT
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's amortization of capitalized software and acquired intangible assets?
ADMA Biologics (ADMA) reported amortization of capitalized software and acquired intangible assets of $55K in Q1 2026.
How has ADMA Biologics's amortization of capitalized software and acquired intangible assets changed year-over-year?
ADMA Biologics's amortization of capitalized software and acquired intangible assets increased by 120.0% year-over-year, from $25K to $55K.
What is the long-term trend for ADMA Biologics's amortization of capitalized software and acquired intangible assets?
Over 4 years (2021 to 2025), ADMA Biologics's amortization of capitalized software and acquired intangible assets has grown at a -32.8% compound annual growth rate (CAGR), from $715K to $146K.